Related Experiment Video
Updated: Aug 16, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
TA-TMA occurring after sequential CD7 CAR-T cell therapy and allogeneic hematopoietic stem cell transplantation: a
Jinlin Zhang1, Li Ma2, Xiu Liu1
1First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Frontiers in Immunology
|August 15, 2026
Summary
Chimeric antigen receptor T-cell (CAR-T) therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a key treatment for blood cancers. This case highlights transplant-associated thrombotic microangiopathy (TA-TMA) as a rare complication after this sequential therapy.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a vital strategy for refractory/relapsed hematologic malignancies.
- This sequential therapy offers a novel approach for T-lymphoid malignancies, CD7-positive acute myeloid leukemia (AML), and mixed phenotype acute leukemia (MPAL).
- It aims to achieve tumor eradication, hematopoietic reconstitution, and prevent graft-versus-host disease (GVHD), while avoiding toxic conventional treatments.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)